REGISTER
Tamim Niazi Previews DASL-HiCaP in Very High-Risk Localized Prostate Cancer
Ahead of the DASL-HiCaP presentation at ESMO 2026, Tamim Niazi explains why the phase 3 trial tested darolutamide alongside androgen deprivation therapy and locoregional radiotherapy, and what question it addresses for patients with very high-risk localized prostate cancer.

0
0
Loading